Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$116K Buy
1,167
+425
+57% +$51.2K ﹤0.01% 1608
2026
Q2
$98.9K Sell
742
-144
-16% -$16.3K ﹤0.01% 1628
2026
Q1
$98.7K Buy
886
+260
+42% +$30.8K ﹤0.01% 1547
2025
Q4
$84.4K Buy
+626
New +$68.3K ﹤0.01% 1556

Other funds holding ABVX

AssetMark's ABVX Position: Q3 2026 in Review

AssetMark increased its Abivax (ABVX) stake by 57% in Q3 2026, buying an estimated $51.2K and bringing the position to 1,167 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #1608.

AssetMark first reported a position in ABVX in Q4 2025 and has held it in 4 quarters since. 221 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • AssetMark held 1,167 shares of Abivax worth $116K as of Q3 2026.
  • AssetMark bought 425 Abivax shares in Q3 2026, an estimated $51.2K.
  • Abivax made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1608 holding.
  • AssetMark first reported a position in Abivax in Q4 2025 and has held it in 4 quarters since.
  • 221 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.